145 related articles for article (PubMed ID: 38671361)
1. Behavioral changes in patients with Prader-Willi syndrome receiving diazoxide choline extended-release tablets compared to the PATH for PWS natural history study.
Strong TV; Miller JL; McCandless SE; Gevers E; Yanovski JA; Matesevac L; Bohonowych J; Ballal S; Yen K; Hirano P; Cowen NM; Bhatnagar A
J Neurodev Disord; 2024 Apr; 16(1):22. PubMed ID: 38671361
[TBL] [Abstract][Full Text] [Related]
2. Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial.
Miller JL; Gevers E; Bridges N; Yanovski JA; Salehi P; Obrynba KS; Felner EI; Bird LM; Shoemaker AH; Angulo M; Butler MG; Stevenson D; Abuzzahab J; Barrett T; Lah M; Littlejohn E; Mathew V; Cowen NM; Bhatnagar A;
J Clin Endocrinol Metab; 2023 Jun; 108(7):1676-1685. PubMed ID: 36639249
[TBL] [Abstract][Full Text] [Related]
3. A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome.
Kimonis V; Surampalli A; Wencel M; Gold JA; Cowen NM
PLoS One; 2019; 14(9):e0221615. PubMed ID: 31545799
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and relationship between hyperphagia, anxiety, behavioral challenges and caregiver burden in Prader-Willi syndrome.
Kayadjanian N; Vrana-Diaz C; Bohonowych J; Strong TV; Morin J; Potvin D; Schwartz L
PLoS One; 2021; 16(3):e0248739. PubMed ID: 33765021
[TBL] [Abstract][Full Text] [Related]
5. Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial.
Roof E; Deal CL; McCandless SE; Cowan RL; Miller JL; Hamilton JK; Roeder ER; McCormack SE; Roshan Lal TR; Abdul-Latif HD; Haqq AM; Obrynba KS; Torchen LC; Vidmar AP; Viskochil DH; Chanoine JP; Lam CKL; Pierce MJ; Williams LL; Bird LM; Butler MG; Jensen DE; Myers SE; Oatman OJ; Baskaran C; Chalmers LJ; Fu C; Alos N; McLean SD; Shah A; Whitman BY; Blumenstein BA; Leonard SF; Ernest JP; Cormier JW; Cotter SP; Ryman DC
J Clin Endocrinol Metab; 2023 Jun; 108(7):1696-1708. PubMed ID: 36633570
[TBL] [Abstract][Full Text] [Related]
6. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study.
Whitman BY; Myers S; Carrel A; Allen D
Pediatrics; 2002 Feb; 109(2):E35. PubMed ID: 11826245
[TBL] [Abstract][Full Text] [Related]
7. Alteration of serum leptin and LEP/LEPR promoter methylation in Prader-Willi syndrome.
Wieting J; Jahn K; Buchholz V; Lichtinghagen R; Deest-Gaubatz S; Bleich S; Eberlein CK; Deest M; Frieling H
Psychoneuroendocrinology; 2022 Sep; 143():105857. PubMed ID: 35803048
[TBL] [Abstract][Full Text] [Related]
8. Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial.
McCandless SE; Yanovski JA; Miller J; Fu C; Bird LM; Salehi P; Chan CL; Stafford D; Abuzzahab MJ; Viskochil D; Barlow SE; Angulo M; Myers SE; Whitman BY; Styne D; Roof E; Dykens EM; Scheimann AO; Malloy J; Zhuang D; Taylor K; Hughes TE; Kim DD; Butler MG
Diabetes Obes Metab; 2017 Dec; 19(12):1751-1761. PubMed ID: 28556449
[TBL] [Abstract][Full Text] [Related]
9. Clinical Trials in Prader-Willi Syndrome: A Review.
Mahmoud R; Kimonis V; Butler MG
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768472
[TBL] [Abstract][Full Text] [Related]
10. The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria.
Gunay-Aygun M; Schwartz S; Heeger S; O'Riordan MA; Cassidy SB
Pediatrics; 2001 Nov; 108(5):E92. PubMed ID: 11694676
[TBL] [Abstract][Full Text] [Related]
11. Hypomethylation of the dopamine transporter (DAT) gene promoter is associated with hyperphagia-related behavior in Prader-Willi syndrome: A case-control study.
Wieting J; Jahn K; Eberlein CK; Bleich S; Frieling H; Deest M
Behav Brain Res; 2023 Jul; 450():114494. PubMed ID: 37182741
[TBL] [Abstract][Full Text] [Related]
12. Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome.
Dykens EM; Miller J; Angulo M; Roof E; Reidy M; Hatoum HT; Willey R; Bolton G; Korner P
JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925684
[TBL] [Abstract][Full Text] [Related]
13. Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome.
Salehi P; Hsu I; Azen CG; Mittelman SD; Geffner ME; Jeandron D
Pediatr Obes; 2017 Jun; 12(3):221-228. PubMed ID: 27071367
[TBL] [Abstract][Full Text] [Related]
14. Intranasal oxytocin versus placebo for hyperphagia and repetitive behaviors in children with Prader-Willi Syndrome: A randomized controlled pilot trial.
Hollander E; Levine KG; Ferretti CJ; Freeman K; Doernberg E; Desilva N; Taylor BP
J Psychiatr Res; 2021 May; 137():643-651. PubMed ID: 33190843
[TBL] [Abstract][Full Text] [Related]
15. Calorie seeking, but not hedonic response, contributes to hyperphagia in a mouse model for Prader-Willi syndrome.
Davies JR; Humby T; Dwyer DM; Garfield AS; Furby H; Wilkinson LS; Wells T; Isles AR
Eur J Neurosci; 2015 Aug; 42(4):2105-13. PubMed ID: 26040449
[TBL] [Abstract][Full Text] [Related]
16. AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial.
Allas S; Caixàs A; Poitou C; Coupaye M; Thuilleaux D; Lorenzini F; Diene G; Crinò A; Illouz F; Grugni G; Potvin D; Bocchini S; Delale T; Abribat T; Tauber M
PLoS One; 2018; 13(1):e0190849. PubMed ID: 29320575
[TBL] [Abstract][Full Text] [Related]
17. A disease specific questionnaire for assessing behavior in individuals with Prader-Willi syndrome.
Avrahamy H; Pollak Y; Shriki-Tal L; Genstil L; Hirsch HJ; Gross-Tsur V; Benarroch F
Compr Psychiatry; 2015 Apr; 58():189-97. PubMed ID: 25677112
[TBL] [Abstract][Full Text] [Related]
18. Oxytocin in young children with Prader-Willi syndrome: Results of a randomized, double-blind, placebo-controlled, crossover trial investigating 3 months of oxytocin.
Damen L; Grootjen LN; Juriaans AF; Donze SH; Huisman TM; Visser JA; Delhanty PJD; Hokken-Koelega ACS
Clin Endocrinol (Oxf); 2021 May; 94(5):774-785. PubMed ID: 33296519
[TBL] [Abstract][Full Text] [Related]
19. Malignancies in Prader-Willi Syndrome: Results From a Large International Cohort and Literature Review.
Pellikaan K; Nguyen NQC; Rosenberg AGW; Coupaye M; Goldstone AP; Høybye C; Markovic T; Grugni G; Crinò A; Caixàs A; Poitou C; Corripio R; Nieuwenhuize RM; van der Lely AJ; de Graaff LCG
J Clin Endocrinol Metab; 2023 Nov; 108(12):e1720-e1730. PubMed ID: 37267430
[TBL] [Abstract][Full Text] [Related]
20. Caregiver priorities for endpoints to evaluate treatments for Prader-Willi syndrome: a best-worst scaling.
Tsai JH; Scheimann AO; McCandless SE; Strong TV; Bridges JFP
J Med Econ; 2018 Dec; 21(12):1230-1237. PubMed ID: 30256699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
